PR Newswire·Feb 6, 2026, 4:15 PM ET

Azitra Announces Adjournment of Special Meeting and Information for Reconvened Special Meeting

Azitra Inc. adjourned its Special Meeting, originally scheduled for February 6, 2026, until March 6, 2026, at 11:00 a.m. Eastern Time due to the absence of a quorum.
A quorum required 33 1/3% of outstanding voting shares but was not met as only approximately 13% of shares had submitted proxies by the time of the adjournment.
The Reconvened Special Meeting will remain in a virtual format accessible via www.proxydocs.com/AZTR using the control number from the proxy card.
Proposal One seeks approval to issue more than 19.99% of common stock underlying warrants pursuant to a November 24, 2025 Securities Purchase Agreement with Alumni Capital LP to comply with NYSE American rules.
Proposal Two allows for further adjournment of the meeting if necessary to solicit additional proxies regarding the primary proposal.
Eligible stockholders of record as of January 2, 2026, are urged to vote or change their proxies by 10:59 a.m. Eastern Time on March 6, 2026.
Voting methods include mailing the proxy card, submitting electronically at www.proxypush.com/AZTR, or voting by telephone using the toll-free number on the proxy card.
Azitra's lead program ATR-12 utilizes engineered S. epidermidis to treat Netherton syndrome, while program ATR-04 targets EGFR inhibitor-associated rash with FDA Fast Track designation.